Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2025 | 2666 | 1.290 |
Why?
|
| Breast Neoplasms | 21 | 2025 | 3303 | 1.280 |
Why?
|
| Pyridines | 9 | 2024 | 317 | 1.090 |
Why?
|
| Triple Negative Breast Neoplasms | 6 | 2025 | 218 | 0.880 |
Why?
|
| Antineoplastic Agents | 9 | 2024 | 2386 | 0.770 |
Why?
|
| Kidney Neoplasms | 7 | 2019 | 556 | 0.750 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2019 | 384 | 0.570 |
Why?
|
| Neoadjuvant Therapy | 8 | 2024 | 477 | 0.540 |
Why?
|
| Capecitabine | 4 | 2024 | 103 | 0.540 |
Why?
|
| Benzenesulfonates | 2 | 2008 | 49 | 0.520 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2024 | 527 | 0.400 |
Why?
|
| Watchful Waiting | 3 | 2024 | 77 | 0.390 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 641 | 0.390 |
Why?
|
| Neoplasm Staging | 13 | 2025 | 2087 | 0.380 |
Why?
|
| Carcinoma, Small Cell | 2 | 2017 | 116 | 0.370 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 62 | 0.350 |
Why?
|
| Prostatic Neoplasms | 5 | 2022 | 1846 | 0.350 |
Why?
|
| Middle Aged | 35 | 2025 | 29642 | 0.350 |
Why?
|
| Aged | 31 | 2025 | 21986 | 0.350 |
Why?
|
| Lung Neoplasms | 5 | 2018 | 2474 | 0.350 |
Why?
|
| Urologic Neoplasms | 2 | 2024 | 82 | 0.350 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2024 | 642 | 0.350 |
Why?
|
| Receptors, Estrogen | 4 | 2024 | 431 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2025 | 1538 | 0.330 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2024 | 246 | 0.330 |
Why?
|
| Bevacizumab | 8 | 2022 | 255 | 0.320 |
Why?
|
| Aged, 80 and over | 18 | 2024 | 7461 | 0.320 |
Why?
|
| Students, Medical | 3 | 2023 | 450 | 0.310 |
Why?
|
| Receptors, Progesterone | 3 | 2024 | 208 | 0.310 |
Why?
|
| Neoplasms | 6 | 2023 | 3382 | 0.300 |
Why?
|
| Medical Oncology | 3 | 2019 | 426 | 0.300 |
Why?
|
| Radiosurgery | 3 | 2021 | 352 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 995 | 0.290 |
Why?
|
| Humans | 53 | 2025 | 98799 | 0.290 |
Why?
|
| Anilides | 3 | 2019 | 50 | 0.290 |
Why?
|
| Female | 38 | 2025 | 51997 | 0.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 1177 | 0.270 |
Why?
|
| Adult | 26 | 2025 | 29698 | 0.270 |
Why?
|
| Prostatectomy | 2 | 2021 | 491 | 0.250 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 316 | 0.250 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 58 | 0.240 |
Why?
|
| Piperazines | 3 | 2024 | 308 | 0.230 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 305 | 0.230 |
Why?
|
| Pyrroles | 2 | 2017 | 166 | 0.230 |
Why?
|
| Weight Reduction Programs | 1 | 2025 | 14 | 0.230 |
Why?
|
| Disease-Free Survival | 7 | 2024 | 1196 | 0.220 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2019 | 191 | 0.220 |
Why?
|
| Neutropenia | 3 | 2021 | 211 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2024 | 21 | 0.220 |
Why?
|
| Indoles | 2 | 2017 | 340 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2024 | 37 | 0.210 |
Why?
|
| Nitriles | 3 | 2024 | 172 | 0.210 |
Why?
|
| Trastuzumab | 2 | 2021 | 98 | 0.200 |
Why?
|
| Creatinine | 1 | 2024 | 315 | 0.200 |
Why?
|
| Weight Loss | 1 | 2025 | 247 | 0.200 |
Why?
|
| Aspirin | 1 | 2024 | 168 | 0.190 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2024 | 158 | 0.190 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 403 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 583 | 0.180 |
Why?
|
| Androgen Antagonists | 2 | 2021 | 157 | 0.180 |
Why?
|
| Vegetables | 2 | 2020 | 50 | 0.180 |
Why?
|
| Treatment Outcome | 11 | 2025 | 9806 | 0.180 |
Why?
|
| Interdisciplinary Studies | 2 | 2019 | 19 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 255 | 0.180 |
Why?
|
| ErbB Receptors | 1 | 2005 | 517 | 0.180 |
Why?
|
| Schools, Medical | 2 | 2023 | 137 | 0.180 |
Why?
|
| Carboplatin | 5 | 2025 | 331 | 0.170 |
Why?
|
| Paclitaxel | 5 | 2025 | 484 | 0.170 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 238 | 0.170 |
Why?
|
| Oxazoles | 1 | 2021 | 14 | 0.170 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 121 | 0.170 |
Why?
|
| Double-Blind Method | 5 | 2024 | 1793 | 0.170 |
Why?
|
| Clinical Competence | 2 | 2018 | 873 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 1105 | 0.160 |
Why?
|
| Postmenopause | 2 | 2024 | 109 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 161 | 0.160 |
Why?
|
| Oncologists | 1 | 2021 | 43 | 0.160 |
Why?
|
| Triazoles | 2 | 2024 | 118 | 0.160 |
Why?
|
| Male | 21 | 2024 | 47475 | 0.160 |
Why?
|
| Quinazolines | 1 | 2021 | 222 | 0.150 |
Why?
|
| Leukemia | 1 | 2022 | 310 | 0.150 |
Why?
|
| Testosterone | 1 | 2021 | 266 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 220 | 0.150 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 1102 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2021 | 281 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2025 | 829 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 127 | 0.140 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.140 |
Why?
|
| Age Factors | 1 | 2023 | 1976 | 0.140 |
Why?
|
| Diet | 2 | 2022 | 472 | 0.140 |
Why?
|
| Obesity | 1 | 2025 | 1079 | 0.140 |
Why?
|
| Survival Analysis | 4 | 2021 | 1530 | 0.130 |
Why?
|
| Counseling | 1 | 2020 | 191 | 0.130 |
Why?
|
| Niacinamide | 2 | 2008 | 105 | 0.130 |
Why?
|
| Prospective Studies | 5 | 2023 | 4837 | 0.130 |
Why?
|
| Disease Progression | 5 | 2021 | 1621 | 0.130 |
Why?
|
| Phenylurea Compounds | 2 | 2008 | 112 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 101 | 0.120 |
Why?
|
| Health Services Misuse | 1 | 2016 | 20 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 1422 | 0.120 |
Why?
|
| Curriculum | 2 | 2019 | 643 | 0.120 |
Why?
|
| Survival Rate | 5 | 2019 | 2057 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 233 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 3622 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 1786 | 0.120 |
Why?
|
| Prognosis | 5 | 2023 | 4139 | 0.120 |
Why?
|
| Quality of Life | 5 | 2025 | 1904 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 4049 | 0.110 |
Why?
|
| Deoxycytidine | 3 | 2025 | 218 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2016 | 174 | 0.110 |
Why?
|
| Mifepristone | 2 | 2025 | 59 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 455 | 0.100 |
Why?
|
| Area Under Curve | 2 | 2018 | 341 | 0.100 |
Why?
|
| Pediatrics | 1 | 2018 | 422 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 331 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 1215 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2024 | 909 | 0.090 |
Why?
|
| Telephone | 2 | 2025 | 43 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2016 | 476 | 0.090 |
Why?
|
| Young Adult | 5 | 2024 | 7598 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 925 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 2 | 2025 | 265 | 0.080 |
Why?
|
| Intention to Treat Analysis | 2 | 2024 | 82 | 0.080 |
Why?
|
| Sirolimus | 1 | 2012 | 181 | 0.080 |
Why?
|
| Hospitalization | 1 | 2016 | 993 | 0.080 |
Why?
|
| Fatigue | 3 | 2017 | 187 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2024 | 11104 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1128 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 1754 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2018 | 1132 | 0.070 |
Why?
|
| Placebos | 1 | 2008 | 210 | 0.070 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 239 | 0.070 |
Why?
|
| Oncogenes | 1 | 2007 | 102 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2024 | 1949 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 2 | 2020 | 356 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 923 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2007 | 519 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 978 | 0.050 |
Why?
|
| Thrombocytopenia | 2 | 2017 | 194 | 0.050 |
Why?
|
| Albumins | 1 | 2025 | 126 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2024 | 54 | 0.050 |
Why?
|
| Purines | 1 | 2024 | 97 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 837 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 70 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2024 | 120 | 0.050 |
Why?
|
| Canada | 1 | 2024 | 210 | 0.050 |
Why?
|
| Contrast Media | 1 | 2008 | 1014 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2023 | 3242 | 0.050 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2025 | 145 | 0.050 |
Why?
|
| Abiraterone Acetate | 1 | 2023 | 14 | 0.050 |
Why?
|
| Risk Factors | 3 | 2020 | 6295 | 0.050 |
Why?
|
| United States | 3 | 2024 | 8387 | 0.050 |
Why?
|
| Androstenes | 1 | 2023 | 42 | 0.050 |
Why?
|
| Phenylthiohydantoin | 1 | 2023 | 58 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2024 | 677 | 0.050 |
Why?
|
| Prednisone | 1 | 2023 | 252 | 0.050 |
Why?
|
| Cancer Survivors | 1 | 2024 | 110 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 333 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2023 | 119 | 0.040 |
Why?
|
| Benzamides | 1 | 2023 | 260 | 0.040 |
Why?
|
| Time Factors | 2 | 2021 | 5586 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 325 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2025 | 869 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2021 | 69 | 0.040 |
Why?
|
| Radiation Oncologists | 1 | 2021 | 15 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 3058 | 0.040 |
Why?
|
| Breast | 1 | 2023 | 317 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2021 | 92 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 205 | 0.040 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 28 | 0.040 |
Why?
|
| Perception | 1 | 2021 | 190 | 0.040 |
Why?
|
| Hypertension | 2 | 2017 | 791 | 0.040 |
Why?
|
| Learning | 1 | 2023 | 313 | 0.040 |
Why?
|
| Mastectomy | 1 | 2021 | 277 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 244 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 356 | 0.040 |
Why?
|
| Cisplatin | 1 | 2021 | 578 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 259 | 0.030 |
Why?
|
| Training Support | 1 | 2018 | 23 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2019 | 177 | 0.030 |
Why?
|
| Prostate | 1 | 2022 | 434 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2018 | 23 | 0.030 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 23 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 122 | 0.030 |
Why?
|
| Hemoptysis | 1 | 2018 | 27 | 0.030 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 36 | 0.030 |
Why?
|
| Celecoxib | 1 | 2017 | 34 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2017 | 79 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2017 | 76 | 0.030 |
Why?
|
| Platinum Compounds | 1 | 2017 | 29 | 0.030 |
Why?
|
| Mucositis | 1 | 2017 | 18 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2019 | 243 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2017 | 35 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 404 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 349 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2007 | 3642 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 96 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 728 | 0.030 |
Why?
|
| Selection Bias | 1 | 2016 | 40 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 135 | 0.030 |
Why?
|
| Standard of Care | 1 | 2016 | 71 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1895 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 147 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 828 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 2026 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 285 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 285 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 1798 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 1226 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 2604 | 0.020 |
Why?
|
| Remission Induction | 1 | 2014 | 764 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2577 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2016 | 609 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2011 | 543 | 0.020 |
Why?
|
| Child | 1 | 2018 | 7771 | 0.010 |
Why?
|
| Chicago | 1 | 2011 | 1520 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 4443 | 0.010 |
Why?
|